

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**FOR THE MONTH OF JUNE 2020  
COMMISSION FILE NUMBER 001-39081**

**BioNTech SE**

(Translation of registrant's name into English)

**An der Goldgrube 12 D-  
55131 Mainz Germany  
+49 6131-9084-0**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form  
20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K**

On June 26, 2020, BioNTech SE (the “Company”) conducted its Annual General Meeting (AGM) for shareholders in Munich, Germany. The shareholder voting results overview are attached hereto as Exhibit 99.1.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BioNTech SE**

By: /s/ Dr. Sierk Poetting  
Name: Dr. Sierk Poetting  
Title: Chief Financial Officer

Date: June 26, 2020

---

## EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	Annual General Meeting in Munich, Germany, June 26, 2020 Voting Results.

## Voting results - Overview - Only the German version is binding

<b>Agenda Item 2</b>	<b>Approval of the actions of the Management Board - accepted</b>		
	152,033,174	Number of shares for which valid votes were cast (= 63.826 % of the registered share capital)	
	152,015,170	Yes votes	99.988 % of the valid votes cast
	18,004	No votes	0.012 % of the valid votes cast
<b>Agenda Item 3</b>	<b>Approval of the actions of the Supervisory Board - accepted</b>		
	73,516,708	Number of shares for which valid votes were cast (= 30.864 % of the registered share capital)	
	73,497,269	Yes votes	99.974 % of the valid votes cast
	19,439	No votes	0.026 % of the valid votes cast
<b>Agenda Item 4</b>	<b>Appointment of the auditor for the 2020 financial year - accepted</b>		
	195,931,883	Number of shares for which valid votes were cast (= 82.256 % of the registered share capital)	
	195,927,278	Yes votes	99.998 % of the valid votes cast
	4,605	No votes	0.002 % of the valid votes cast
<b>Agenda Item 5</b>	<b>Amendment of the authorization to issue stock options - accepted</b>		
	195,518,062	Number of shares for which valid votes were cast (= 82.082 % of the registered share capital)	
	195,449,670	Yes votes	99.965 % of the valid votes cast
	68,392	No votes	0.035 % of the valid votes cast
<b>Agenda Item 6</b>	<b>Expansion of options to exclude subscription rights for authorised capital - accepted</b>		
	195,507,877	Number of shares for which valid votes were cast (= 82.078 % of the registered share capital)	
	195,492,290	Yes votes	99.992 % of the valid votes cast
	15,587	No votes	0.008 % of the valid votes cast
<b>Agenda Item 7</b>	<b>Amendments to the Articles of Association in connection with the invitation to and conduct of general meetings - accepted</b>		
	195,487,103	Number of shares for which valid votes were cast (= 82.069 % of the registered share capital)	
	193,271,471	Yes votes	98.867 % of the valid votes cast
	2,215,632	No votes	1.133 % of the valid votes cast
<b>Agenda Item 8a</b>	<b>Approval of the conclusion of the domination agreement between the Company as controlling company and BioNTech Small Molecules GmbH as dependent company - accepted</b>		
	195,511,012	Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)	
	195,505,708	Yes votes	99.997 % of the valid votes cast
	5,304	No votes	0.003 % of the valid votes cast
<b>Agenda Item 8b</b>	<b>Approval of the conclusion of the domination agreement between the Company as controlling company and BioNTech IVAC GmbH as de-pendent company - accepted</b>		
	195,510,926	Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)	
	195,505,442	Yes votes	99.997 % of the valid votes cast
	5,484	No votes	0.003 % of the valid votes cast

## Voting results - Overview - Only the German version is binding

**Agenda Item 8c** Approval of the conclusion of the domination agreement between the Company as controlling company and BioNTech Real Estate Holding GmbH as dependent company - accepted

195,510,844	Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)	
195,504,260	Yes votes	99.997 % of the valid votes cast
6,584	No votes	0.003 % of the valid votes cast

**Agenda Item 8d** Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company - accepted

195,511,026	Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)	
195,503,722	Yes votes	99.996 % of the valid votes cast
7,304	No votes	0.004 % of the valid votes cast

**Agenda Item 8e** Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Cell & Gene Therapies GmbH as dependent company - accepted

195,511,435	Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)	
195,504,552	Yes votes	99.996 % of the valid votes cast
6,883	No votes	0.004 % of the valid votes cast